Low-dose fractionated radiation potentiates the effects of paclitaxel in wild-type and mutant p53 head and neck tumor cell lines

Clinical Cancer Research

Volumn 9, Issue 4, 2003, Pages 1557-1565

  Dey, Swatee ^a   Spring, Paul M ^a,b   Arnold, Suzanne ^a   Valentino, Joseph ^a,b   Chendil, Damodaran ^a   Regine, William F ^a,b   Mohiuddin, Mohammed ^a,b   Ahmed, Mansoor M ^a,b,c  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MUTANT PROTEIN; PACLITAXEL; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53;

ARTICLE; BAX GENE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL CYCLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG POTENTIATION; GENE; GENE TARGETING; HEAD AND NECK CARCINOMA; HUMAN; INTERMETHOD COMPARISON; P21 GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE; RADIOSENSITIVITY; UPREGULATION; WILD TYPE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BINDING SITES; BLOTTING, WESTERN; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; HEAD AND NECK NEOPLASMS; HELA CELLS; HUMANS; IN SITU NICK-END LABELING; KINETICS; MUTATION; NF-KAPPA B; PACLITAXEL; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0037386761     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Jemal, A., Thomas, A., Murray, T., and Thun, M. Cancer statistics, 2002. CA Cancer J. Clin., 52: 23-47, 2002.
2. Landis, S. H., Murray, T., Bolden, S., and Wingo, P. A. Cancer statistics. CA Cancer J. Clin., 49: 8-31, 1999.
3. Vokes, E. E., W. R., Lippman, S. M., and Hong, W. K. Head and neck cancer. N. Engl. J. Med., 328: 184-194, 1993.
4. Suntharalingam, M., Hans, M. L., Conley, B. A., Egorin, M. J., Levy, S., Sivasailam, S., Herman, J. M., Jacobs, M. C., Gray, W. C., Ord, R. A., Aisner, J. A., and Van Echo, D. A. The use of carboplatin and paclitaxel with daily radiotherapy in patients with locally advanced squamous cell carcinomas of the head and neck. Int. J. Radiat. Oncol. Biol. Phys., 47: 49-56, 2000.
5. Chen, Y., Sato, M., Fujimura, S., Endo, C., Sakurada, A., Aikawa, H., Takahashi, H., Tanita, T., Kondo, T., Saito, Y., and Sagawa, M. Expression of Bcl-2, Bax, and p53 proteins in carcinogenesis of squamous cell lung cancer. Anticancer Res., 19: 1351-1356, 1999.
6. Kroemer, G. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat. Med., 3: 614-620, 1997.
7. Chendil, D., Oakes, R., Alcock, R. A., Patel, N., Mayhew, C., Mohiuddin, M., Gallicchio, V. S., and Ahmed, M. M. Low dose fractionated radiation enhances the radiosensitization effect of paclitaxel in colorectal tumor cells with mutant p53. Cancer, 89: 1893-1900, 2000.
8. Kastan, M. B., Canman, C. E., and Leonard, C. J. P53, cell cycle control and apoptosis: implications for cancer. Cancer Metastisis Rev., 14: 3-15, 1995.
9. Lowe, S. W., Ruley, H. E., Jacks, T., and Housman, D. E. P53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74: 957-967, 1993.
10. Rowinskey, E. K., Onetta, N., Canetta, R. M., and Arbuck, S. G. Taxol: the first of the taxanes, an important new class of antitumor agents. Semin. Oncol., 19: 646-662, 1992.
11. Rose, W. C. Taxol: a review of its preclinical in vivo antitumor activity. Anticancer Drugs, 3: 311-321, 1992.
12. Steren, A., Sevin, B. U., Perras, J., Angioli, R., Nguyen, H., Guerra, L., Koechli, O., and Averette, H. E. Taxol sensitizes human ovarian cancer cells to radiation. Gynecol. Oncol., 48: 252-258, 1993.
13. Tishler, R. B., Geard, C. R., Hall, E. J., and Schiff, P. B. Taxol sensitizes human astrocytoma cells to radiation, Cancer Res., 52: 3495-3497, 1992.
14. Saito, Y., Milross, C. G., Hittelman, W. N., Li, D., Jibu, T., Peters, L. J., and Milas, L. Effect of radiation and Paclitaxel on p53 expression in murine tumors sensitive of resistant to apoptosis induction. Int. J. Radiat. Oncol. Biol. Phys., 38: 623-631, 1997.
15. Joiner, M. C. Induced radioresistance: an overview and historical perspective. Int. J. Radiat. Biol., 65: 79-84, 1994.
16. Lambin, P., Marples, B., Fertil, B., Malaise, E. P., and Joiner, M. C. Hypersensitivity of a human tumour cell line to very low radiation doses. Int. J. Radiat. Biol., 63: 639-650, 1993.
17. Marples, B., Lambin, P., Skov, K. A., and Joiner, M. C. Low dose hyper-radiosensitivity and increased radioresistance in mammalian cells. Int. J. Radiat. Biol., 71: 721-735, 1997.
18. Wouters, B. G., and Skarsgard, L. D. The response of a human tumor cell line to low radiation doses: evidence of enhanced sensitivity. Radiat. Res., 138: S76-S80, 1994.
19. Joiner, M. C., Marples, B., Lambin, P., Short, S. C., and Turesson, I. Low-dose hypersensitivity: current status and possible mechanisms. Int. J. Radiat. Oncol. Biol. Phys., 49: 379-389, 2001.
20. Joiner, M. C., Rojas, A., and Johns, H. Renal damage in the mouse: the response to very small doses per fraction. Radiat. Res., 114: 385-398, 1998.
21. Short, S., Mayes, C., Woodcock, M., Johns, H., and Joiner, M. C. Low dose hypersensitivity in the T98g human glioblastoma cell line. Int. J. Radiat. Biol., 75: 847-855, 1999.
22. Nagasawa, H., Keng, P., Maki, C., Yu, Y., and Little, J. B. Absence of a radiation-induced first-cycle GI-S arrest in p53+ human tumor cells synchronized by mitotic selection. Cancer Res., 58: 2036-2041, 1998.
23. Mira Jung, V. N., and Dritschilo, A. Mutations in the p53 gene in radiation-sensitive and resistant human squamous carcinoma cells. Cancer Res., 52: 6390-6393, 1992.
24. Nair, P., Muthukumar, S., Sells, S. F., Han, S. S., Sukhatme, V. P., and Rangneka, V. M. J. Biol. Chem., 272: 20131-20138, 1997.
25. Ahmed, M. M., Sells, S. F., Venkatasubbarao, K., Fruitwala, S. M., Muthukkumar, S., Harp, C., Mohiuddin, M., and Rangnekar, V. M. Ionizing radiation inducible apoptosis in the absence of p53 linked to transcription factor EGR-1. J. Biol. Chem., 272: 33056-33061, 1997.
26. Chendil, D., Das, A., Dey, D., Mohiuddin, M., and Ahmed, M. M. Par-4, a pro-apoptotic gene, inhibits NFkB activity resulting in the repression of radiation-induced BCL-2 expression leading to induction of radiosensitivity in human prostate cancer cells PC-3. Cancer Biol. Ther., 1: 152-160, 2002.
27. el-Deiry, W. S., O'Connor, P. M., Velculescu, V. E., Canman, C. E., Jackman, J., Pietenpol, J. A., Bunel, M., and Hill, D. E. WAF1/ CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res., 54: 1169-1174, 1994.
28. Harper, J. W., Elledge, S. J., Keyomarsi, K., Dynlacht, B., Tsai, L. H., Zhan, P., Dobrowolski, S., Bai, C., Connell-Crowley, L., and Swindell, E. Inhibition of cyclin-dependent kinases by p21. Mol. Biol. Cell, 6: 387-400, 1995.
29. Demers, G. W., Foster, S. A., Halbert, C. L., and Galloway, D. A. Growth arrest by induction of p53 in DNA damaged keratinocytes is bypassed by human papillomavirus 16 E7. Proc. Natl. Acad. Sci. USA, 91: 4382-4386, 1994.
30. Lu, X. and Lane, D. P. Differential induction of transcriptionally active p53 following UV or ionizing radiation: defects in chromosome instability syndromes? Cell, 75: 765-778, 1993.
31. Fritsche, M., Haessler, C., and Brandner, G. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene, 8: 307-318, 1993.
32. Ramsamooj, P., Kasid, U., and Dritschilo, A. Differential expression of proteins in radioresistant and radiosensitive human squamous carcinoma cells. J. Natl. Cancer Inst. (Bethesda), 84: 1992.
33. Weichselbaum, R. R., Dahlberg, W., Beckett, M., Karrison, T., Miller, D., Clark, J., and Ervin, T. J. Radiation-resistant and repair proficient human tumor cells maybe associated with radiotherapy failure in head and neck cancer patients. Proc. Natl. Acad. Sci. USA, 83: 2684-2688, 1986.
34. Coral, A., Quiet, R. R. W., and Grdina, D. J. Variation in radiation sensitivity during the cell cycle of two human squamous cell carcinomas. Int. J. Radiat. Oncol. Biol. Phys., 20: 733-738, 1991.
35. Lee, J. M. and Bernstein, A., p53 mutations increase resistance to ionizing radiation. Proc. Natl. Acad. Sci. USA, 90: 5742-5746, 1993.
36. Oltavi, Z. N., Milliman, C. L., and Korsemeyer, S. J. Bcl-2 heterodimerizes in vitro with a conserved homolog, BAX, that accelerates programmed cell death. Cell, 74: 609-619, 1993.
37. Chen, M., Quintans, J., Fuks, Z., Thompson, C., Kufe, D. W., and Weichselbaum, R. R. Suppression of Bcl-2 messenger RNA production may mediate apoptosis after ionizing radiation, tumor necrosis factor α, and ceramide. Cancer Res., 55: 991-994, 1995.
38. Kariya, S., Ogawa, Y., Yoshida, S., Yabuki, M., Imajo, Y., and Utsumi, K. X-irradiation enhances the expression of Bcl-2 in HL-60 cells: the resulting effects on apoptosis and radiosensitivity. Int. J. Mol. Med., 3: 145-152, 1999.
39. Pradier, O. M., Rave-Frank, M., Schmidberger, H., Bomecke, M., Lehman, J., Meden, H., and Hess, C-F. Effects of paclitaxel in combination with radiation on human head and cnek cancer cells (ZMK-1), cervical squamous cell carcinoma (CaSki), and breast adenocarcinoma cells (MCF-7). J. Cancer Res. Clin. Oncol., 125: 20-27, 1999.
40. Liebmann, J., C. J., Fisher, J., et al. In vitro studies of paclitaxel as a radiation sensitizer in human tumor cells. J. Natl. Cancer Inst. (Bethesda), 86: 441-446, 1994.